NYSE:BLCO Bausch + Lomb (BLCO) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free BLCO Stock Alerts $17.30 +0.09 (+0.52%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$17.15▼$17.5350-Day Range$13.69▼$17.6052-Week Range$13.62▼$21.95Volume365,527 shsAverage Volume447,532 shsMarket Capitalization$6.07 billionP/E RatioN/ADividend YieldN/APrice Target$19.68 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Bausch + Lomb alerts: Email Address Bausch + Lomb MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside13.8% Upside$19.68 Price TargetShort InterestHealthy3.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth35.38%From $0.65 to $0.88 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.50 out of 5 starsMedical Sector337th out of 938 stocksOphthalmic Goods Industry3rd out of 7 stocks 3.3 Analyst's Opinion Consensus RatingBausch + Lomb has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.68, Bausch + Lomb has a forecasted upside of 13.8% from its current price of $17.30.Amount of Analyst CoverageBausch + Lomb has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.22% of the float of Bausch + Lomb has been sold short.Short Interest Ratio / Days to CoverBausch + Lomb has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bausch + Lomb has recently decreased by 20.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBausch + Lomb does not currently pay a dividend.Dividend GrowthBausch + Lomb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLCO. Previous Next 2.6 News and Social Media Coverage News SentimentBausch + Lomb has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Bausch + Lomb this week, compared to 3 articles on an average week.Search Interest10 people have searched for BLCO on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat Follows3 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch + Lomb insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 11.07% of the stock of Bausch + Lomb is held by institutions. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Bausch + Lomb are expected to grow by 35.38% in the coming year, from $0.65 to $0.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch + Lomb is -23.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch + Lomb is -23.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBausch + Lomb has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBausch + Lomb has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Bausch + Lomb Stock (NYSE:BLCO)Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.Read More BLCO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLCO Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comBLCO Apr 2024 17.500 callMarch 7, 2024 | msn.comBenchmark upgrades Emergent Biosolutions to BuyMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 28, 2024 | finance.yahoo.comBausch + Lomb Announces Appointment of Karen L. Ling to Board of DirectorsFebruary 26, 2024 | markets.businessinsider.comBarclays Maintains Equal-Weight Rating for Bausch & Lomb: Here's What You Need To KnowFebruary 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Bausch + Lomb Corporation (BLCO) and Eli Lilly & Co (LLY)February 23, 2024 | msn.comBausch + Lomb Stock Jumps After Better-Than-Expected Earnings, GuidanceFebruary 23, 2024 | finance.yahoo.comBausch + Lomb Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 22, 2024 | finance.yahoo.comBHC Feb 2024 10.000 putFebruary 22, 2024 | finance.yahoo.comBausch + Lomb Corporation (NYSE:BLCO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | realmoney.thestreet.comBausch + Lomb price target raised by $2 at Wells Fargo, here's whyFebruary 22, 2024 | finance.yahoo.comQ4 2023 Bausch + Lomb Corp Earnings CallFebruary 21, 2024 | msn.comBausch & Lomb’s stock soars 9% after earnings beatFebruary 21, 2024 | markets.businessinsider.comNeedham Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO)February 21, 2024 | msn.comEye Care-Focused Bausch + Lomb's Stock Surges On Upbeat Annual Guidance Despite Deeper LossesFebruary 21, 2024 | msn.comBausch & Lomb’s stock soars 11% after earnings beatFebruary 21, 2024 | reuters.comEmergent appoints former Bausch + Lomb CEO to head companyFebruary 21, 2024 | msn.comBLCO Earnings: Bausch + Lomb Outperforms in Q4, Shares JumpFebruary 21, 2024 | msn.comBausch + Lomb gains after earnings beatFebruary 21, 2024 | markets.businessinsider.comEmergent BioSolutions Appoints Joseph Papa As President And CEOFebruary 21, 2024 | markets.businessinsider.comBausch + Lomb Q4 Adj. Net Income RisesFebruary 21, 2024 | finance.yahoo.comEmergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEOFebruary 21, 2024 | finance.yahoo.comBausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 GuidanceFebruary 21, 2024 | finance.yahoo.comBausch & Lomb Corp (BLCO) Reports Robust Revenue Growth Amidst Net Loss in Q4 and Full-Year 2023February 21, 2024 | seekingalpha.comBausch + Lomb Corporation 2023 Q4 - Results - Earnings Call PresentationFebruary 20, 2024 | msn.comBausch + Lomb Q4 2023 Earnings PreviewSee More Headlines Receive BLCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Ophthalmic goods Sub-IndustryN/A Current SymbolNYSE:BLCO CUSIPN/A CIK1860742 Webwww.bausch.com Phone905-695-7700FaxN/AEmployees13,300Year FoundedN/APrice Target and Rating Average Stock Price Target$19.68 High Stock Price Target$25.00 Low Stock Price Target$16.00 Potential Upside/Downside+13.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E Ratio26.62 P/E Growth1.63Net Income$-260,000,000.00 Net Margins-6.27% Pretax Margin-4.00% Return on Equity3.70% Return on Assets2.11% Debt Debt-to-Equity Ratio0.65 Current Ratio1.74 Quick Ratio1.09 Sales & Book Value Annual Sales$4.15 billion Price / Sales1.46 Cash Flow$1.95 per share Price / Cash Flow8.86 Book Value$19.72 per share Price / Book0.88Miscellaneous Outstanding Shares350,996,000Free FloatN/AMarket Cap$6.07 billion OptionableOptionable Beta0.35 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Osama A. Eldessouky (Age 52)Executive VP & CFO Comp: $1.09MDr. Yehia Hashad M.D. (Age 57)Executive VP of Research & Development and Chief Medical officer Comp: $1.09MMr. Brenton L. Saunders J.D. (Age 54)CEO & Chairman Mr. Alan Waterhouse CPFA (Age 64)MBA, Executive VP and Chief Supply Chain & Operations Officer Mr. Frederick J. Munsch (Age 53)Senior VP, Controller & Chief Accounting Officer Mr. A. Robert D. Bailey (Age 61)Executive VP & Chief Legal Officer Mr. Jonathon L. KellermanChief Compliance OfficerT.J. CrawfordChief Communications OfficerDr. Manisha A. Narasimhan Ph.D. (Age 47)Chief Corporate Development & Digital Officer Ms. Asli GevgililiExecutive VP & Chief Human Resources OfficerMore ExecutivesKey CompetitorsRxSightNASDAQ:RXSTSTAAR SurgicalNASDAQ:STAANational VisionNASDAQ:EYECooper CompaniesNASDAQ:COOCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInstitutional OwnershipQuadrature Capital LtdBought 20,803 shares on 3/25/2024Ownership: 0.014%Goldman Sachs Group Inc.Bought 70,071 shares on 3/1/2024Ownership: 0.020%FIL LtdBought 855,250 shares on 2/17/2024Ownership: 2.312%Gamco Investors INC. ET ALSold 2,900 shares on 2/15/2024Ownership: 0.015%Barclays PLCBought 10,283 shares on 2/15/2024Ownership: 0.003%View All Institutional Transactions BLCO Stock Analysis - Frequently Asked Questions Should I buy or sell Bausch + Lomb stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BLCO shares. View BLCO analyst ratings or view top-rated stocks. What is Bausch + Lomb's stock price target for 2024? 10 Wall Street analysts have issued 12 month target prices for Bausch + Lomb's shares. Their BLCO share price targets range from $16.00 to $25.00. On average, they expect the company's stock price to reach $19.68 in the next year. This suggests a possible upside of 13.8% from the stock's current price. View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts. How have BLCO shares performed in 2024? Bausch + Lomb's stock was trading at $17.06 at the start of the year. Since then, BLCO shares have increased by 1.4% and is now trading at $17.30. View the best growth stocks for 2024 here. Are investors shorting Bausch + Lomb? Bausch + Lomb saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 1,230,000 shares, a decline of 20.1% from the February 29th total of 1,540,000 shares. Based on an average trading volume of 449,000 shares, the short-interest ratio is presently 2.7 days. Currently, 3.2% of the shares of the stock are short sold. View Bausch + Lomb's Short Interest. When is Bausch + Lomb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our BLCO earnings forecast. How were Bausch + Lomb's earnings last quarter? Bausch + Lomb Co. (NYSE:BLCO) released its earnings results on Wednesday, February, 21st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.07. The company earned $1.17 billion during the quarter, compared to the consensus estimate of $1.11 billion. Bausch + Lomb had a positive trailing twelve-month return on equity of 3.70% and a negative net margin of 6.27%. The business's revenue for the quarter was up 17.8% on a year-over-year basis. During the same quarter last year, the business posted $0.23 EPS. What ETFs hold Bausch + Lomb's stock? ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX). What guidance has Bausch + Lomb issued on next quarter's earnings? Bausch + Lomb issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.6 billion-$4.7 billion, compared to the consensus revenue estimate of $6.1 billion. When did Bausch + Lomb IPO? Bausch + Lomb (BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share. Who are Bausch + Lomb's major shareholders? Bausch + Lomb's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FIL Ltd (2.31%), River Road Asset Management LLC (0.55%), Freshford Capital Management LLC (0.50%), Whitebox Advisors LLC (0.27%), Victory Capital Management Inc. (0.16%) and Gabelli Funds LLC (0.09%). How do I buy shares of Bausch + Lomb? Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:BLCO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.